Login to Your Account



newco news NEWS

With $22 million in series A fuel and technology licensed from Harvard University, Macrolide Pharmaceuticals Inc. is "blowing out the class" of antibiotics after which the company is named "in a very rapid and efficient manner," explained CEO and co-founder Lawrence Miller.

Companies that emerge from academic institutions enjoy the special advantage of intimate familiarity with a new molecular entity or drug platform but also face the special challenge of contending with bigger and better financed organizations. 

DUBLIN – Prexton Therapeutics SA, an early stage CNS drug developer spun out of the Merck Serono arm of Merck KGaA, raised €8.7 million (US$10 million) to move a metabotropic glutamate receptor 4 (mGluR4) agonist development program into clinical trials in Parkinson's disease.
More newco news Headlines

Cast Your Vote

Has biotech’s bubble burst?: